The New England journal of medicine, 2018-12, Vol.379 (23), p.2220-2229
- Horn, Leora
- Mansfield, Aaron S
- Szczęsna, Aleksandra
- Havel, Libor
- Krzakowski, Maciej
- Hochmair, Maximilian J
- Huemer, Florian
- Losonczy, György
- Johnson, Melissa L
- Nishio, Makoto
- Reck, Martin
- Mok, Tony
- Lam, Sivuonthanh
- Shames, David S
- Liu, Juan
- Ding, Beiying
- Lopez-Chavez, Ariel
- Kabbinavar, Fairooz
- Lin, Wei
- Sandler, Alan
- Liu, Stephen V
2018
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Horn, Leora
- Mansfield, Aaron S
- Szczęsna, Aleksandra
- Havel, Libor
- Krzakowski, Maciej
- Hochmair, Maximilian J
- Huemer, Florian
- Losonczy, György
- Johnson, Melissa L
- Nishio, Makoto
- Reck, Martin
- Mok, Tony
- Lam, Sivuonthanh
- Shames, David S
- Liu, Juan
- Ding, Beiying
- Lopez-Chavez, Ariel
- Kabbinavar, Fairooz
- Lin, Wei
- Sandler, Alan
- Liu, Stephen V
- Titel
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- Ist Teil von
- The New England journal of medicine, 2018-12, Vol.379 (23), p.2220-2229
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2018
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In a randomized trial, the addition of atezolizumab to carboplatin and etoposide resulted in significantly longer overall survival than carboplatin and etoposide alone (12.3 months vs. 10.3 months).
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1809064Titel-ID: cdi_proquest_miscellaneous_2116124812
- Format
- –
- Schlagworte
- Aged, Antibodies, Monoclonal - administration & dosage, Antibodies, Monoclonal - adverse effects, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Apoptosis, Cancer therapies, Carboplatin, Carboplatin - administration & dosage, Chemotherapy, Clinical trials, Committees, Cytotoxicity, Death, Double-Blind Method, Etoposide, Etoposide - administration & dosage, Female, Humans, Immunotherapy, Kaplan-Meier Estimate, Lung cancer, Lung Neoplasms - drug therapy, Lung Neoplasms - mortality, Lungs, Lymphocytes T, Male, Metastasis, Middle Aged, Monoclonal antibodies, Motivation, Neoplasm Staging, Patients, PD-1 protein, PD-L1 protein, Progression-Free Survival, Response rates, Small cell lung carcinoma, Small Cell Lung Carcinoma - drug therapy, Small Cell Lung Carcinoma - mortality, Solid tumors, Targeted cancer therapy, Tumors